Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
Weight suppression appears to result in future onset of eating disorders characterized by dietary restriction or compensatory weight control behaviours, suggesting weight-suppressed women represent an at-risk group that may benefit from selective prevention programmes, a study has found.
3 days ago
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.

Factors predicting malignant progression in Barret’s oesophagus patients

22 Apr 2018

Factors such as Barret’s oesophagus (BE) length, presence of low-grade dysplasia (LGD) and nodularity increase the risk of progression from nondysplastic (ND)BE or LGD to high-grade dysplasia (HGD) or oesophageal adenocarcinoma (EAC), a study has found.

The study included 318 NDBE patients and 301 BE-LGD patients (mean age, 62.6 years; 85 percent male). Those who developed HGD/EAC >12 months after the initial NDBE or LGD diagnosis were considered progressors.

During a mean follow-up of 5.3 years, seven NDBE and 21 LGD patients progressed to HGD/EAC.

In multivariate Cox proportional hazards models, progression was independently predicted by the following: BE length (hazards ratio [HR], 1.16; 95 percent CI, 1.03–1.29), baseline LGD (HR, 2.57; 1.13-6.57) and presence of nodularity (HR, 4.98; 1.80–11.7).

Of note, demographic (eg, age and sex) and lifestyle factors (eg, BMI and tobacco use) did not influence the risk of malignant progression. This is in line with reports from previous studies. [Ann Surg 2005;242:49-54; Am J Gastroenterol 2006;101:2187-2193; Gastroenterol Clin North Am 2015;44:299-315]

The predictive factors reported in the present study could help identify high-risk BE patients who would benefit from endoscopic therapy rather than surveillance, researchers said.

The study was limited by the inclusion of participants from tertiary referral centres, the small number of progressors in each patient group, and lack of data on alcohol and medication use.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
Weight suppression appears to result in future onset of eating disorders characterized by dietary restriction or compensatory weight control behaviours, suggesting weight-suppressed women represent an at-risk group that may benefit from selective prevention programmes, a study has found.
3 days ago
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.